Resolution of pulmonary oedema is mediated by active absorption of liquid across the alveolar epithelium. A key component of this process is the sodium-potassium ATPase (Na ϩ K ϩ -ATPase) enzyme located on the basolateral surface of epithelial cells and up-regulated during oedema resolution. We hypothesised that lung liquid clearance could be further up-regulated by lipid-mediated transfer and expression of exogenous Na ϩ K ϩ -ATPase cDNA. We demonstrate proof of this principle in a model of high permeability pulmonary oedema induced by intraperitoneal injection of thiourea (2.5 mg/kg) in C57/BL6 mice. Pretreatment of mice (24 h before thiourea) by nasal sniffing of cationic liposome (lipid #67)-DNA complexes encoding the ␣ and ␤ subunits of Na ϩ K ϩ -ATPase (160 g per mouse), significantly (P Ͻ 0.01) decreased the wet:dry weight ratios measured 2 h after
Introduction
Resolution of pulmonary oedema is now known to be mediated by active absorption of liquid across the alveolar epithelium. [1] [2] [3] [4] While the mechanisms remain only partially understood, most data suggest that the driving force for this process is active sodium transport via apically located amiloride-sensitive channels and basolaterally located, ouabain-sensitive sodium-potassium ATPase (Na + K + -ATPase) pumps. 5 This process generates a transepithelial osmotic gradient and water moves out of the alveoli as a secondary phenomenon. Thus, the alveolar epithelium functions not only as an important barrier to alveolar flooding but also as an active organ in the reabsorption process. Maintenance of its structural and functional integrity has been shown to be an important determinant of the outcome of lung injury. thiourea injection compared with control animals, pretreated with an equivalent dose of an irrelevant gene. Whole lung Na ϩ K ϩ -ATPase activity was significantly (P Ͻ 0.05) increased in mice pretreated with Na ϩ K ϩ -ATPase cDNA compared both with untreated control animals as well as animals pretreated with the irrelevant gene. Nested RT-PCR on whole lung homogenates confirmed gene transfer by detection of vector-specific mRNA in three of four mice studied 24 h after gene transfer. This demonstration of a significant reduction in pulmonary oedema following in vivo gene transfer raises the possibility of gene therapy as a novel, localised approach for pulmonary oedema in clinical settings such as ARDS and lung transplantation. Gene Therapy (2000) 7, 960-966.
meric proteins containing at least three subunits (␣, ␤ and ␥), each of which exists as a number of isoforms. [7] [8] [9] Of these, only the ␣ and ␤ subunits are thought to be of functional significance in the mammalian lung. 10 The larger (112 kDa) ␣ subunit contains the domains directly involved in ion translocation and ATP hydrolysis as well as binding sites for substrates and inhibitors of enzyme function. The smaller (55 kDa) ␤ subunit is a glycoprotein thought to control heterodimer assembly and membrane insertion. 11 Both subunits are required for functional expression of normal Na + K + -ATPase activity. 11, 12 In the lung, the protein is expressed in alveolar type I and type II cells and both expression and function of the enzyme appears to be developmentally regulated. Thus, in the foetal rat lung, for example, Na + K + -ATPase mRNA, protein and function increase just before birth 10, 13 while in the developing mouse lung, a dramatic increase in ␣ and ␤ 1 -mRNA has been documented just before birth. 14 Further, in the rabbit lung, alveolar type II cells have been shown to raise their Na + K + -ATPase activity perinatally. 15 All of these observations point to a central role for Na + K + -ATPase in the generation and maintenance of 'dry' alveoli at a crucial time when the lungs need to clear liquid as they adapt to air breathing.
A large body of evidence now also suggests that in the developed lung, clearance of lung liquid remains related to active sodium transport and hence to Na + K + -ATPase activity. Up-regulation of alveolar fluid transport secondary to increased sodium transport by alveolar epithelial cells has been demonstrated in isolated type II alveolar cells, 16, 17 isolated lungs ex vivo, 18, 19 and in a number of alveolar flooding models induced either by liquid instillation [1] [2] [3] or by acute lung injury using hyperoxia, 20 endotoxin or bacterial pneumonia. 21, 22 Further, ouabain, a specific inhibitor of Na + K + -ATPase, depresses sodium 18, 19 and liquid 4, 19, 23 transport in isolated lungs. The most compelling evidence for the role of Na + K + -ATPase in the resolution of pulmonary oedema derives from an in vivo model of high permeability pulmonary oedema induced in rats by intraperitoneal thiourea. 24 This study demonstrated that lung Na + K + -ATPase activity was increased, particularly in alveolar type II cells, during recovery from oedema. This, in part, related to an increased Na + K + -ATPase protein production in the lung. Enzyme activity began to increase 4 h after the induction of oedema, approximately 2 h after maximal pulmonary oedema. Activity reached maximal levels at 12 h and was associated with marked resolution of the oedema, providing evidence that this active sodium transport mechanism is endogenously up-regulated during this resolution process.
We hypothesised that lung liquid clearance and hence oedema resolution could be further up-regulated by transfer and expression of exogenous Na 
Results
Effects of intraperitoneal thiourea on C57BL/6 micecharacterisation of a mouse model of high permeability pulmonary oedema Thiourea has previously been used to induce pulmonary oedema in rats. 25 Because gene delivery in mice is a well established technique, we assessed the administration of thiourea in C57BL/6 mice. Incremental doses of thiourea resulted in a dose-dependent increase in pulmonary oedema as evidenced by increases in lung wet-to-dry weight ratios in mice 6 h following treatment (Figure 1a) . Wet-todry weight ratios were maximal at 5-10 mg/kg. Thiourea treatment was also associated with the generation of pleural effusions (Figure 1b) . This was similarly dose-dependent, maximal at 5-10 mg/kg, but was not seen at the lowest dose tested (1 mg/kg). Mice treated with thiourea doses higher than 2.5 mg/kg exhibited decreased activity and increased respiratory effort 1-2 h following administration, compatible with alveolar oedema, but all animals recovered 24 h following administration.
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Thiourea-induced pulmonary oedema was time-dependent ( Figure 1c) . Thus, at a dose of 2.5 mg/kg, wet-todry weight ratios peaked at 2 h following treatment and declined gradually over the following 24 h. The timecourse of pleural fluid development differed (Figure 1d) , with maximal levels 1 h later than the maximal wet-todry weight ratio; thus, pleural effusions followed the increase in pulmonary oedema. These studies allowed us to select conditions maximising pulmonary oedema but minimising pleural effusions (2.5 mg/kg thiourea at 2 h after treatment). The effects of gene transfer on resolution of alveolar oedema could then be assessed in the absence of the potentially confounding variable of pleural fluid, the resolution of which may be mediated through different mechanisms and at a different rate.
In vivo studies to confirm efficacy of gene transfer and expression Intranasal administration of liposome-DNA complexes is a well established method of gene delivery to the large airways of mice lungs. To confirm efficient delivery to the alveolar regions, required for these studies, methylene blue was instilled intranasally in C57BL/6 mice and could be detected throughout the lung tissue, with the trachea, large airways and lung parenchyma showing extensive staining (data not shown). Further, to confirm effective gene transfer and expression by this route of delivery, the reporter gene encoding chloramphenicol acetyltransferease (pCF1-CAT, 160 g per mouse) complexed with the cationic liposome #67 was instilled intranasally. Whole lung CAT activity, assessed 24 h later significantly increased following gene transfer ( Figure 2 ). Previous studies have demonstrated that this whole lung CAT expression is approximately equally distributed between large airways and the parenchyma. 26 Effects of liposome-mediated transfer of pCINaK on thiourea-induced pulmonary oedema Compared with control mice treated with thiourea alone, pretreatment with pCINaK-lipid #67 complexes 24 h before thiourea administration significantly (P Ͻ 0.005) reduced wet-to-dry weight ratios in thiourea-treated mice ( Figure 3 ). These ratios were also significantly (P Ͻ 0.01) lower than those observed in mice pretreated with the irrelevant gene encoding CAT. Mice treated with CAT cDNA showed wet-to-dry weight ratios not significantly different from mice treated with thiourea alone.
Effects of liposome-mediated transfer of pCINaK on whole lung Na
We assessed whether pCINaK augmented Na
Whole lung enzyme activity in mice treated 2 h before being killed with thiourea was not significantly increased compared with untreated animals ( Figure 4 ). However, mice pretreated with Na
+ -ATPase cDNA demonstrated significantly (P Ͻ 0.05) higher enzyme activity 2 h after thiourea compared with animals treated with thiourea alone or with animals pretreated with the control cDNA cDNA encoding CAT. There was no significant difference in lung DNA recovery between any of the treatment groups where the mean DNA per lung recovered was baseline 1.05 ± 0.11 mg, thiourea only 0.95 ± 0.15 mg, pCINaK followed by thiourea 1.06 ± 0.11 mg and pCF1-CAT followed by thiourea 1.13 ± 0.06 mg. 
Figure 1 Characterisation of a model of high permeability pulmonary oedema in C57BL/6 mice. The effect of intraperitoneal injection of different doses of thiourea on the lung wet-to-dry weight ratios (a) and the development of pleural effusions (b) in C57BL/6 mice killed 6 h after treatment. Data are mean ± s.e.m. (n ϭ 4-6), presented as % above baseline wet-to-dry weight ratio which was 3.87 ± 0.05 (n = 8). Statistically different (*P Ͻ 0.01) compared with baseline values when n numbers are sufficient for comparison. The effect of time on thiourea-induced pulmonary oedema (c) and pleural effusions (d). No fluid was recovered from untreated controls or from treated mice at the 1 and 24-h time-points. Data are presented as mean

Confirmation of vector-specific gene expression
Twenty-four hours after gene transfer, reverse transcription PCR (RT-PCR) was carried out using mRNA purified from mouse lungs. A vector-specific product derived from Na 
Discussion
In this study, we show that in vivo resolution of pulmonary oedema may be significantly enhanced by pretreatment of the lungs with Na + K + -ATPase gene transfer. This was associated with increased lung Na + K + -ATPase activity and detection of vector-specific mRNA confirming successful gene transfer. These observations support the hypothesis that exogenous up-regulation of Na + K + -ATPase, over and above the inherent capacity of the endogenous enzyme to up-regulate acutely in response to oedema formation, can augment lung liquid clearance.
To our knowledge this is the first in vivo demonstration of this principle. Our results extend into a disease model, in vivo, the findings of a recent study using adenoviruses encoding either the ␣ 1 or the ␤ 1 subunit of Na The in vitro component of this study 27 provided substantial evidence that the vectors used were capable of efficient gene transfer without cytotoxicity, and that Na -uptake and sodium transport, could be specifically augmented following gene transfer. Non-diseased rat lungs were then studied ex vivo following prior gene transfer. Difficulties were encountered with the induction of inflammatory changes by the viral vector. Consequently, the ex vivo measurements of lung liquid clearance were made 7 days after gene transfer, under conditions of ongoing epithelial barrier dysfunction characterised by generalised epithelial permeability to both sodium and mannitol. This 7-day time-point corresponds more closely to the 'subacute' phase of resolution of alveolar epithelial injury, 28 characterised by proliferation of alveolar type II cells. The potential clinical use
Gene Therapy of such gene therapy is likely to be at an earlier timepoint when such proliferation is not evident.
The study by Factor et al 27 identified functional changes following transfer of the ␤ 1 but not the ␣ 1 subunit. This was considered to be due to availability of the ␤ 1 subunit being rate-limiting in rat alveolar epithelium. Experiments in which either exogenous ␣ or ␤ subunit or both are transferred separately are inherently complex. Either subunit or both may contain specific targeting information and the recipient cells which recognise these signals also express their own pumps, the subunits of which can assemble with exogenous subunits even when both ␣ and ␤ are expressed at high levels. To maximise the chances of a functional ATPase being produced, we used cDNA encoding a 'single-subunit' Na + -pump, called '␣-␤' in which the chicken ␤ 1 subunit is linked to the carboxyl terminus of the chicken ␣ 3 subunit by 17 amino acids. 29 Despite its chicken origin, the functional integrity of this construct has previously been demonstrated in a number of mammalian cell lines. Transfection of mammalian cells resulted in expression of functional, ouabaininhibitable Na + K + -ATPase, folded and assembled as they are in the native enzyme and targeted to the correct surface domains of the basolateral membrane. 29 Resolution of pulmonary oedema following pCINaK transfer was not complete despite prior optimisation of gene transfer efficiency. 26 Improvements in transfection efficiency may enhance this process. However, other components of the complex machinery of lung water clearance may need to be considered. Thus, while Na + K + -ATPase is thought to be the principal driving force for vectorial sodium and water transport across the alveolar epithelium, the epithelial sodium channel, EnaC, 30 and the aquaporin water channels 31, 32 are also involved in lung liquid clearance. Increased Na + K + -ATPase activity must be associated with increased sodium ion entry at the apical surface of epithelial cells and thus increased ENaC expression may also be required. Further, in vivo transepithelial water transport may be enhanced more than three times above basal levels following adeno-associated viral gene transfer of cDNA encoding the human aquaporin 1. 33 Thus, cotransfection of cDNA for either or both of these components may ultimately be needed to achieve further augmentation of lung liquid clearance.
Increased lung liquid accumulation was easily demonstrable in C57BL/6 mice following treatment with thiourea. In contrast, no increases were observed in BALB/c mice following similar or even higher doses of thiourea. This in turn may be secondary to higher basal levels of lung Na + K + -ATPase activity observed in these BALB/c mice (data not shown) compared with C57BL/6 animals. Precedents for these differences exist. Genetic variation in patterns of nephron function during natriuresis in different strains of mice is well documented. 34 Further, basal Na + K + -ATPase activity in human bronchial epithelium is higher in subjects with cystic fibrosis (CF), compared with non-CF subjects. 35 Understanding the mechanisms of these differences may be important in optimising protocols for Na
In conclusion, we present evidence for the use of gene therapy to accelerate lung liquid clearance in vivo. Although these studies provide only proof of principle in a mouse model in which gene transfer was applied as pretreatment, before the onset of lung injury, these data suggest this approach may be applied clinically. The acute, and inevitable, pulmonary oedema associated with the reperfusion syndrome following lung transplantation 36 may, for example, be an important clinical target where pretreatment of donor organs may be sufficient to prevent the development of pulmonary oedema. Adult respiratory distress syndrome remains a disease with a high mortality, and while this relates principally to multiorgan failure, an important study has shown that patients who were able to reabsorb some of the oedema fluid within 12 h of intubation after acute lung injury, recovered more rapidly from respiratory failure and had a lower mortality. 6 This study also showed that the ability of the alveolar epithelial barrier to reabsorb fluid following acute lung injury is preserved in 30% to 40% of patients. Thus, preselection of patients known to be at high risk of developing ARDS and manipulation of the epithelial barrier with Na 
Materials and methods
Animal model of pulmonary oedema Adult male C57BL/6 mice of weights between 17 and 23 g (Charles River, Kent, UK) were used. The animals were maintained in a pathogen-free environment at 19°C, 50% humidity and had unlimited access to food and water. Pulmonary oedema was induced by a single intraperitoneal (i.p.) injection of thiourea (Sigma, Poole, UK) dissolved in sterile saline at concentrations which ranged from 0.25 to 100 mg/kg. Mice were killed between 1 and 24 h following thiourea administration.
Assessment of oedema
Pleural fluid collection: Immediately after death the pleural cavity was opened close to the sternum and fluid, if present, removed with a Pasteur pipette, transferred into pre-weighed Eppendorf tubes and the volume determined by weighing the tubes.
Estimation of lung wet-to-dry weight ratios: The trachea and oesophagus were separated from the lung by blunt dissection. The remaining tissue was removed and immediately weighed in pre-weighed Petri dishes. The lungs were subsequently dried overnight at 55°C to remove all moisture. The dry weight was then measured and the ratio of wet-to-dry weight determined. 
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Determination of DNA concentration in cell lysates: Aliquots of lung homogenate were added to cold 10% trichloracetic acid (TCA) and left at 4°C for 4 h to precipitate DNA and protein. Following centrifugation and further incubation at 90°C for 30 min, samples were incubated overnight with the chromogenic solution comprising diphenylamine solution (1.5 g diphenylamine in 100 ml glacial acetic acid with 1.5 ml concentrated sulphuric acid) and a 2% acetaldehyde solution. Supernatants were aspirated following centrifugation and DNA concentration was calculated spectrophotometrically (OD 600 ). + -ATPase activity was measured by a modified phosphate release assay employing ␥-
32
P as a tracer, as previously described. 24 Briefly, lung homogenates were added to a buffer containing 120 mm NaCl, 20 mm KCl, 7.5 mm MgCl 2 , 1 mm EGTA, 5 mm sodium azide, 25 mm imidazole, with or without 2 mm ouabain, for 20 min on ice and for 1 min at 37°C. 100 l of ␥-
ATP solution (45 mm adenosine 5Ј-triphosphate, 25 Ci 32 P-ATP, Amersham, Buckinghamshire, UK) was added to the samples at 30 s intervals, mixed and incubated at 37°C. At 1 min intervals, samples were loaded on to chromatography columns (QS-P Isolab; Genetic Research Instruments, Braintree, UK) on ice containing 1 m perchloric acid and 0.3 m NaH 2 PO 4 . Subsequently, 2% activated charcoal (Sigma) was added to the columns selectively to bind ATP but not P i . Eluate was added to scintillation vials for Cerenkov counting. Controls, composed of assay buffer in the absence of lung homogenate, with or without ouabain were treated as above. Data were analysed by multiple regression with phosphate release as the dependent variable and time as one independent variable. A 'dummy' variable (d = 1 in the absence of ouabain and d = 2 in the presence of ouabain) was used to take account of the influence of ouabain on phosphate release. Na + K + -ATPase activity (mol/h) was taken as the difference between the rate of phosphate release in the presence and absence of ouabain. The induction of oedema by thiourea is associated with increased endothelial permeability and leakage of intravascular protein into the lung parenchyma. Thus, as previously described, 24 enzyme activity was standardised to DNA concentration in the lungs.
Plasmid DNA encoding the Na
The plasmid pBS-␣ 3 -␤ 1 (a gift from Dr D Farmbrough, John Hopkins University, Baltimore, MD, USA) comprised a 4 kb chicken Na + K + -ATPase cDNA in a bluescript vector. 29 The single subunit Na
-ATPase cDNA fragment contained in the plasmid was constructed by Emerick et al by linking the ␣ 3 subunit carboxyl terminus to the ␤ 1 subunit amino terminus with 17 amino acids obtained by translation of residual ␤ 1 5ЈUT. The cDNA, encoding a fusion protein with a calculated molecular mass of 147.5 kDa, was subcloned into the mammalian expression vector pCI (Promega, Southampton, UK) containing the human cytomegalovirus immediate-early promoter/enhancer. The resulting 8.2 kb plasmid was called pCINaK.
Intranasal instillation of liposome-DNA complexes to B57Bl/6 mice Animals were individually anaesthetised in a closed chamber using the inhalational anaesthetic methoxyflurane (Metofane, Mallingckrodt Veterinary, Mundlein, IL, USA). Each animal was removed from the chamber and held vertically while pressure was applied to the lower mandible to immobilise the tongue and prevent swallowing. Lipid-DNA complexes (160 g pCINaK or pCF1-CAT complexed with 120 g Lipid #67 in a total volume of 200 l) was applied dropwise on to the nostrils of the animal and the mixture inhaled by sniffing. All complexing reactions were carried out so that equal volumes of lipid #67 (1.2 mm) were added to the pDNA (4.8 mm; the calculation of the molarity of the pDNA based upon the assumption that the molecular weight of the nucleotides is 330 g per mole).
Reporter gene studies: chloramphenicol acetyl transferease (CAT) assay Lungs were removed in toto from animals and homogenised for 15 s at 24 000 r.p.m. in 0.25 m Tris, pH 8. The homogenate was then freeze-thawed four times and heated for 10 min at 60°C to inactivate endogenous deacetylase activity. Samples were centrifuged and the protein content of the supernatant, composed of the cell lysate, determined as previously described. 37 CAT activity was then determined as previously described. 38 Briefly, cell lysates were incubated with co-factor nbutyryl CoA (Sigma), Tris-HCl and D-threo (dichloroacetyl-1- Reverse transcription polymerase chain reaction (RT-PCR) for pCINaK mRNA Total RNA was isolated using the RNAeasy Mini kit (Qiagen, Hilden, Germany) and samples treated with 1 unit DNase (Pharmacia, St Albans, UK)/g DNA. Reverse transcription was performed using 3 g RNA, 0.5 mm of each dNTP, 100 M random hexamer primers (Pharmacia), 300 units RNA guard (Pharmacia), 10 mm dithiothreitol (DTT), 5× RT buffer (BRL, Paisley, UK) and 200 units reverse transcriptase (Superscript; BRL) in a total volume of 20 l. The reaction was incubated at 37°C for 1 h and heat-inactivated for 10 min at 95°C. Nested PCR reactions were performed with plasmid specific primers, which amplify a 327 bp NaK-ATPase cDNA product (PCR: forward primer: 5Ј-AGT CTC GAA CTT AAG CTG-3Ј, reverse primer 5Ј-GCA GTC CGT GTT GTA TTT-3Ј; nested PCR: forward primer: 5Ј-CAG AAG TTG GTC GTG AGG-3Ј, reverse primer 5Ј-CCT TCT TGA GGT CGT CGA-3Ј) using 150 ng cDNA (for PCR) or 1 l of PCR product (for nested PCR), 200 m dNTP, 50 ng of each primer, 1.5 mm MgCl 2 , 10× PCR buffer (BRL) and 1 unit Taq polymerase in a total volume of 20 l. Thermal cycling was carried out for 30 cycles (20 s 92°C, 30 s 55°C, 60 s 72°C). Negative controls, omitting reverse transcriptase, were performed for all samples. PCR products were separated on 2% agarose gels.
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Statistical analysis
All data are presented as mean ± s.e.m. for convenience where n refers to the numbers of animals. The MannWhitney U test was used for comparisons between interventions and the null hypothesis rejected at P Ͻ 0.05.
